Trials / Unknown
UnknownNCT06157619
Vitrification of Oocytes Matured by CAPA-IVM
Vitrification of In Vitro Matured Oocytes Following the CAPA-IVM Methodology
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Centro de Fertilidad y Reproducción Asistida, Peru · Academic / Other
- Sex
- Female
- Age
- 20 Years – 37 Years
- Healthy volunteers
- Accepted
Summary
It has been reported that the potential of In Vitro matured oocytes might be affected by the vitrification process. In fact, the freezing and thawing procedures routinely used in IVF laboratories, have not yet been adapted to oocytes coming from early antral follicles (normally used for In Vitro Maturation). This study aims to compare 2 existing protocols for the Vitrification of In Vitro matured oocytes.
Detailed description
This is a single-center non-blinded observational study. The proposed study will follow a sibling oocyte design in infertile patients. In Vitro Maturation will be performed by using the Capacitation-IVM (CAPA-IVM) methodology. All cumulus-oocyte complexes (COC) recovered from the patient will be cultured in CAPA medium for 24 hours and then matured for 30 hours (IVM). A minimum of 10 metaphase II (MII) stage oocytes are expected from each CAPA-IVM procedure. After CAPA-IVM culture, the mature oocytes (MII) will be randomly divided (50/50) into two groups to be subjected to the two vitrification protocols. In a second step (next cycle), the oocytes from each group will be thawed and fertilized by Intracytoplasmic sperm injection (ICSI). The derived embryos will be cultured to the blastocyst stage (Day 5/6). The transfer of a single embryo (the one with the best quality) will be carried out. The remaining embryos will be vitrified.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Oocyte Vitrification /Warming | In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-05-01
- Completion
- 2025-03-01
- First posted
- 2023-12-06
- Last updated
- 2023-12-06
Locations
1 site across 1 country: Peru
Source: ClinicalTrials.gov record NCT06157619. Inclusion in this directory is not an endorsement.